EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Beyond the two‐trials rule

Leonhard Held iD

Statistics in Medicine · 2024

DOI: 10.1002/sim.10055 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Statistics in Medicine, 2024. Verfasst von Leonhard Held. Beteiligte Einrichtung: Epidemiology, Biostatistics and Prevention Institute (EBPI) and Center for Reproducible Science (CRS), University of Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Drug Approval. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The two‐trials rule for drug approval requires “at least two adequate and well‐controlled studies, each convincing on its own, to establish effectiveness.” This is usually implemented by requiring two significant pivotal trials and is the standard regulatory requirement to provide evidence for a new drug's efficacy. However, there is need to develop suitable alternatives to this rule for a number of reasons, including the possible availability of data from more than two trials. I consider the case of up to three studies and stress the importance to control the partial Type‐I error rate, where only some studies have a true null effect, while maintaining the overall Type‐I error rate of the two‐trials rule, where all studies have a null effect. Some less‐known ‐value combination methods are useful to achieve this: Pearson's method, Edgington's method and the recently proposed harmonic mean ‐test. I study their properties and discuss how they can be extended to a sequential assessment of success while still ensuring overall Type‐I error control. I compare the different methods in terms of partial Type‐I error rate, project power and the expected number of studies required. Edgington's method is eventually recommended as it is easy to implement and communicate, has only moderate partial Type‐I error rate inflation but substantially increased project power.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug ApprovalHumansClinical Trials as TopicModels, StatisticalResearch Design

Stichwörter der Autor:innen

Edgington's methodType‐I error controlreplicabilitysequential methods

Autor:innen und Institutionen

  • Epidemiology, Biostatistics and Prevention Institute (EBPI) and Center for Reproducible Science (CRS), University of Zurich, Zurich, Switzerland.

ORCID-Profile: Leonhard Held

Förderung

  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Zitieren

APA

Held, L. (2024). Beyond the two‐trials rule. Statistics in Medicine. https://doi.org/10.1002/sim.10055

Vancouver

Held L. Beyond the two‐trials rule. Statistics in Medicine. 2024. doi:10.1002/sim.10055

BibTeX
@article{Held2024,
  author = {Held, Leonhard},
  title = {Beyond the two‐trials rule},
  journal = {Statistics in Medicine},
  year = {2024},
  doi = {10.1002/sim.10055}
}
Kostenlos starten →